Sartorius has launched a new genetically engineered CHO host cell line designed to improve productivity and efficiency. The company evaluated the cell line across several cell line development (CLD) campaigns, from DNA to lead clone, using multiple therapeutic protein formats. In five‑liter bioreactor studies, the engineered host showed up to a two‑fold increase in expression titers and up to a three‑fold increase in productivity compared with lead clones generated from the original wild‑type...